Is Central Sensitization a Prognostic Indicator in Chronic Nonspecific Low Back Pain?
RecruitingNCT07826546
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This observational study will examine whether signs of increased sensitivity in the nervous system at the beginning of the study are associated with short-term clinical outcomes in adults with chronic nonspecific low back pain. Approximately 180 participants will complete questionnaires about central sensitization, disability, pain, anxiety, and depression at the beginning of the study. After 6 weeks, disability, pain, and the participant's overall perception of change will be assessed again. The researchers will evaluate whether the initial level of central sensitization is associated with meaningful improvement in disability and perceived treatment benefit. Participants will not be assigned to a treatment as part of this study and will continue to receive routine clinical care.
Study details
- Official title
- The Prognostic Role of Central Sensitization in Short-Term Clinical Outcomes in Chronic Nonspecific Low Back Pain
- Conditions
- Sponsor
- Mardin Artuklu University
- Collaborators
- Mardin Training and Research Hospital
- Start date
- 2026-06-01
- Primary completion
- 2027-06-01
- Sex
- All
- Age range
- from 18 Years to 65 Years
- Results posted
- No results posted in this snapshot
- Countries
- Turkey (Türkiye)
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Adults aged 18 to 65 years * Diagnosis of chronic nonspecific low back pain lasting for at least 3 months * Willingness to participate in the study * Ability to provide written informed consent Exclusion Criteria: * Progressive neurological deficit * Inflammatory rheumatic disease * Active malignancy * History of serious spinal trauma or spinal surgery * Cognitive impairment that may prevent completion of the assessments or follow-up * Initiation, dose modification, or change of antidepressant or gabapentinoid treatment within the previous 3 months * Pregnancy, postpartum period, or breastfeeding * Inability to provide informed consent
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT07826546